ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Latest, Q2 2026
8,561
Period ended Jun 30, 2026
Change on a year earlier
+80.5%
4,743 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Geographic revenue — Outside U.S. ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 8,561 | +80.5% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 7,680 | +81.2% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 6,415 | +42.5% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2025 | Sep 30, 2025 | 6,301 | +73.8% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 4,743 | +36.8% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 4,239 | +37.9% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 4,501 | +55.3% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2024 | Sep 30, 2024 | 3,626 | -12.2% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 3,468 | +24.7% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 3,074 | +21.8% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 2,898 | +9.6% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2023 | Sep 30, 2023 | 4,131 | +63.9% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 2,781 | +8.9% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 2,524 | -4.2% | Form 10-Q (filed 2024-04-30) ↗ |
| Q4 2022 | Dec 31, 2022 | 2,643 | -6.4% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2022 | Sep 30, 2022 | 2,519 | -9.5% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 2,553 | -15.9% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 2,635 | -8.0% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2021 | Dec 31, 2021 | 2,824 | -0.6% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2021 | Sep 30, 2021 | 2,783 | +7.9% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 3,036 | +28.9% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 2,864 | +13.2% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Dec 31, 2020 | 2,842 | +9.5% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 2,579 | +6.7% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 2,355 | -1.2% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 2,531 | +15.0% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 2,595 | +10.2% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 2,416 | +8.0% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 2,384 | +1.8% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 2,201 | +1.5% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 2,354 | +0.9% | Form 10-K (filed 2021-02-17) ↗ |
| Q3 2018 | Sep 30, 2018 | 2,236 | +3.2% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 2,343 | +10.4% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 2,168 | -5.5% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 2,332 | – | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 2,166 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 2,122 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 2,295 | – | Form 10-Q (filed 2018-04-27) ↗ |
Breakdown
What makes up geographic revenue — outside u.s. ($m)
Cite this data
StockData. (2026). Eli Lilly Geographic revenue — Outside U.S. ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/rev_geo_nonus
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.